B lymphocyte activation and proliferation

B lymphocyte activation and proliferation is a complex biological process essential for the adaptive immune response, characterized by the transition of resting B cells into active, proliferating effector cells (Janeway et al., 2016). This process is primarily triggered by the binding of antigens to the B-cell receptor (BCR), which initiates a signaling cascade involving kinases like Bruton's tyrosine kinase (BTK) and phosphoinositide 3-kinase (PI3K) (Kurosaki et al., 2010). Co-stimulatory signals from T cells and cytokines, such as B-cell activating factor (BAFF), further drive clonal expansion and differentiation into antibody-secreting plasma cells or memory B cells (Rickert, 2013). Dysregulation of this pathway is central to the pathogenesis of B-cell malignancies, such as chronic lymphocytic leukemia and non-Hodgkin lymphoma, as well as autoimmune conditions like systemic lupus erythematosus (Nature Reviews Cancer, 2015). Although B lymphocyte activation and proliferation is a physiological process rather than a single molecular target, it is the focus of numerous therapeutic interventions. Drugs such as rituximab target the CD20 surface antigen to deplete B cells, while ibrutinib inhibits BTK to disrupt the signaling necessary for proliferation and survival (FDA Label: Rituxan, 2021; FDA Label: Imbruvica, 2022). Consequently, monitoring this process through biomarkers like CD19, CD20, and Ki-67 is vital for assessing disease progression and treatment efficacy.

Other names

B-cell activationB-cell proliferationB-lymphocyte activationB-lymphocyte proliferation

Modulation of B-cell receptor signaling, depletion of B-cell populations via antibody-dependent cellular cytotoxicity, and inhibition of survival/growth factors like BAFF.